Pharmaceutical cost management and access to psychotropic drugs: the U.S. context
about
Does private insurance adequately protect families of children with mental health disorders?Management of newer medications for attention-deficit/hyperactivity disorder in commercial health plans.The relationship of antidepressant prescribing concentration to treatment duration and costBenefit limits for behavioral health care in private health plansMedicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics.Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia.
P2860
Pharmaceutical cost management and access to psychotropic drugs: the U.S. context
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pharmaceutical cost management and access to psychotropic drugs: the U.S. context
@ast
Pharmaceutical cost management and access to psychotropic drugs: the U.S. context
@en
Pharmaceutical cost management and access to psychotropic drugs: the U.S. context
@nl
type
label
Pharmaceutical cost management and access to psychotropic drugs: the U.S. context
@ast
Pharmaceutical cost management and access to psychotropic drugs: the U.S. context
@en
Pharmaceutical cost management and access to psychotropic drugs: the U.S. context
@nl
prefLabel
Pharmaceutical cost management and access to psychotropic drugs: the U.S. context
@ast
Pharmaceutical cost management and access to psychotropic drugs: the U.S. context
@en
Pharmaceutical cost management and access to psychotropic drugs: the U.S. context
@nl
P2860
P1476
Pharmaceutical cost management and access to psychotropic drugs: the U.S. context
@en
P2093
Haiden A Huskamp
P2860
P304
P356
10.1016/J.IJLP.2005.08.004
P577
2005-09-01T00:00:00Z